I. MODIFIED AGREEMENTS

Biotech Co.* (Country; Symbol)

Pharma Co. (Country)

Change from original agreement

Terms/Details (Date)


Depomed Inc. (DEPO)

Biovail Corp. (Canada)

Amended May 2002 deal to include a second dosage formulation of Glumetza (extended-release metformin)

The deal was concurrent with the filing of new drug applications for both the 500-mg and 1,000-mg dosages; Biovail would pay a $25M milestone and royalties to Depomed upon approval of the 500-mg dose, and royalties in the U.S. and Canada on the other dose (4/28)

Isis Pharmaceuticals Inc. (ISIS)

Eli Lilly and Co.

Extended June 2002 alliance in oncology to explore new cancer targets using RNA-directed technologies

The companies had been working on discovering antisense drugs in inflammatory and metabolic diseases before they began work in cancer; terms were not disclosed (5/6)

Titan Pharmaceuticals Inc. (AMEX:TTP)

Vanda Pharmaceuticals Inc.

Vanda acquired worldwide rights to Titan's iloperidone, an antipsychotic agent in Phase III

Vanda got the rights from Novartis Pharma AG, which had licensed them from Titan; all terms of the deal remain the same (6/9)

II. TERMINATED AGREEMENTS

Acambis plc (UK; ACAM)

Baxter Healthcare Corp.

Companies terminated December 2000 deal under which Acambis was to manufacture components of bacterial vaccines for Baxter

Baxter will pay Acambis $19M through January 2006 to end the deal, after halting certain bacterial vaccine projects (5/19)

Basilea Pharmaceutica AG (Switzerland; SWX:BSLN)

F. Hoffmann-La Roche Ltd. (Switzerland)

Roche did not exercise its opt-in rights for BAL5788, a Phase II antibiotic compound

Basilea gained full rights to the compound after its parent company's decision, and plans to move into Phase III in 2H:04 (5/25)

Biomira Inc. (Canada; BIOM)

Merck KGaA (Germany)

Merck returned rights to the Theratope cancer vaccine because more trials would be needed

The decision does not impact their deal on BLP25 Liposome Vaccine, which they entered at the same time as the Theratope deal in 2001; terms were not disclosed (6/7)

Depomed Inc. (DEPO)

Elan Corp. plc (Ireland)

Depomed regained all rights to their work on extended-release formulations of gabapentin, baclofen and losartan

Depomed acquired Elan's 19.9% stake in Depomed Development Ltd., a subsidiary developing the products, for $50,000 (6/7)

Isis Pharmaceuticals Inc. (ISIS)

Elan Corp. plc (Ireland)

Isis acquired Elan's minority interest in their Orasense and HepaSense joint ventures

Elan already had stopped participating in the work; the deal will end any royalty payments to Elan and reduce dividend expenses for Isis (6/9)

Karo Bio AB (Sweden; SSE:KARO) in 1997

Bristol-Myers Squibb Co.

Companies ended alliance focused on targeting thyroid hormone receptors that began

Karo gets all rights back, and said it will focus on developing second-generation compounds in the metabolic area (4/30)

MedImmune Inc. (MEDI)

Wyeth

Companies dissolved their collaboration on the nasal flu vaccine FluMist and a second-generation liquid formulation, CAIV- T

Wyeth gets $25M up front and up to $10M this year, as well as milestones and royalties; MedImmune will acquire Wyeth's distribution facility in Louisville, Ky., and assume worldwide rights and responsibilities (4/26)


Notes:

# The information in the chart does not cover agreements between biotech companies or agricultural agreements.

* Private companies are indicated with an asterisk.

Unless otherwise noted, stock symbols listed are on the Nasdaq market.

AMEX = American Stock Exchange; SSE = Stockholm Stock Exchange; SWX = Swiss Stock Exchange.

No Comments